Sun-Novo(SH:688621) Guoyuan Securities·2024-05-12 06:00Investment Rating - The report maintains a "Buy" rating for the company [4][7]. Core Views - The company has achieved significant revenue growth, with 2023 revenue reaching 930 million (up 37.8%) and a net profit of 180 million (up 18.1%) [2][3]. - The company has established a comprehensive "preclinical + clinical" drug development service platform, enhancing its competitive advantage and customer retention [4]. - The company has a robust order backlog of 2.57 billion (up 28.7% year-on-year), indicating strong future revenue potential [2][3]. Financial Performance - In Q1 2024, the company reported revenue of 250 million (up 8.5%) and a net profit of 72.75 million (up 51.8%) [2][3]. - The company achieved a per capita output value of 747,000 (up 14.6% year-on-year) in 2023 [3]. - The company has initiated over 100 new self-research projects in 2023, bringing the total to over 350 projects [3]. Profit Forecast - Revenue growth rates are projected at 32.63%, 31.66%, and 30.61% for 2024, 2025, and 2026, respectively [4]. - Net profit growth rates are expected to be 39.10%, 36.71%, and 34.92% for the same years [4]. - Earnings per share (EPS) are forecasted to be 2.29, 3.14, and 4.23 yuan per share for 2024, 2025, and 2026, respectively, with corresponding price-to-earnings (P/E) ratios of 24.34, 17.80, and 13.20 [4].